Hillsdale Investment Management Inc. Buys 300 Shares of Insmed Incorporated (NASDAQ:INSM)

Hillsdale Investment Management Inc. raised its position in shares of Insmed Incorporated (NASDAQ:INSM) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,000 shares of the biopharmaceutical company’s stock after acquiring an additional 300 shares during the period. Hillsdale Investment Management Inc.’s holdings in Insmed were worth $3,935,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. grew its holdings in Insmed by 8.7% in the 4th quarter. Sei Investments Co. now owns 362,616 shares of the biopharmaceutical company’s stock valued at $25,035,000 after buying an additional 29,019 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Insmed by 12.3% in the fourth quarter. American Century Companies Inc. now owns 812,780 shares of the biopharmaceutical company’s stock valued at $56,114,000 after acquiring an additional 89,097 shares in the last quarter. Teacher Retirement System of Texas increased its position in Insmed by 24.4% during the fourth quarter. Teacher Retirement System of Texas now owns 48,337 shares of the biopharmaceutical company’s stock worth $3,337,000 after acquiring an additional 9,471 shares during the period. Xponance Inc. raised its stake in Insmed by 23.1% in the 4th quarter. Xponance Inc. now owns 12,689 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 2,380 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Insmed by 52.9% in the 4th quarter. Intech Investment Management LLC now owns 71,227 shares of the biopharmaceutical company’s stock valued at $4,918,000 after purchasing an additional 24,634 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Truist Financial raised their price target on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Morgan Stanley upped their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Finally, Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 2,978 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the transaction, the chief executive officer now owns 392,589 shares in the company, valued at approximately $24,874,439.04. This trade represents a 0.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. The trade was a 5.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is currently owned by company insiders.

Insmed Stock Performance

NASDAQ:INSM opened at $79.92 on Friday. The stock’s 50-day moving average is $77.43 and its 200-day moving average is $73.80. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market cap of $14.47 billion, a P/E ratio of -14.30 and a beta of 1.28.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.